Page values for "Exenatide"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Exenatide
brand	`String`	Byetta (twice-daily), Bydureon BCise (weekly)
structure	`File`
classes	List of `String`, delimiter: `,`	[[GLP-1 receptor agonist]] · [[Antidiabetic medicines\|Antidiabetic]] · First-in-class incretin mimetic
mechanism	`String`	Agonist of the [[GLP-1 receptor]]; exendin-4 derivative from Gila monster venom.
uses	`String`	[[Type 2 diabetes mellitus]] (adjunct, second-line)
starting_dose	`String`	Byetta: 5 µg SC twice daily, within 60 min before morning and evening meals'"`UNIQ--ref-000000E3-QINU`"' · Bydureon BCise: 2 mg SC once weekly'"`UNIQ--ref-000000E4-QINU`"'
preparations	`String`	Byetta pre-filled multi-dose pen: 5 µg / 10 µg per dose'"`UNIQ--ref-000000E5-QINU`"' · Bydureon BCise single-dose autoinjector: 2 mg extended-release microsphere suspension'"`UNIQ--ref-000000E6-QINU`"'
fda_max	`String`	10 µg twice daily (Byetta)'"`UNIQ--ref-000000E7-QINU`"' · 2 mg once weekly (Bydureon BCise)'"`UNIQ--ref-000000E8-QINU`"'
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Subcutaneous (abdomen • thigh • upper arm)'"`UNIQ--ref-000000E9-QINU`"'
onset	`String`	Glycemic effect within hours (Byetta); weeks (Bydureon, extended-release microsphere)'"`UNIQ--ref-000000EA-QINU`"'
duration	`String`	~10 hours (Byetta)'"`UNIQ--ref-000000EB-QINU`"' · ~7 days steady-state (Bydureon, after ~6–7 weeks of weekly dosing to reach steady state)'"`UNIQ--ref-000000EC-QINU`"'
halflife	`String`	~2.4 hours (Byetta, short, hence the BID schedule)'"`UNIQ--ref-000000ED-QINU`"' · Effective release half-life ~2 weeks (Bydureon)'"`UNIQ--ref-000000EE-QINU`"'
bioavailability	`String`	SC ~65%–75%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
pregnancy	`String`	Avoid. Discontinue before planned pregnancy.'"`UNIQ--ref-000000EF-QINU`"'
legal	`String`	Rx-only;'"`UNIQ--ref-000000F0-QINU`"' not a controlled substance